Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response

British Journal of Cancer

Volumn 111, Issue 4, 2014, Pages 696-707

  Domanitskaya, N ^a   Wangari Talbot, J ^a   Jacobs, J ^a   Peiffer, E ^a   Mahdaviyeh, Y ^a   Paulose, C ^a   Malofeeva, E ^a   Foster, K ^a   Cai, K Q ^a   Zhou, Y ^a   Egleston, B ^a   Hopper Borge, E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

ABCC10; allograft; breast cancer; docetaxel; mammary tumour; metastases; migration; Multidrug Resistance Protein; paclitaxel

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 7;

ABCC10 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIZATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MICE, SCID; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM TRANSPLANTATION; PACLITAXEL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAXOIDS; TISSUE ARRAY ANALYSIS; TUMOR BURDEN;

EID: 84906094943     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.326     Document Type: Article

References (56)

1. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE (2013) Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 15(1-2): 50-61.
2. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, Ulrich RG, Slatter JG (2006) Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36(10-11): 963-988.
3. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4(3): 226-235.
4. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19(2): 185-193.
5. Borel F, Han R, Visser A, Petry H, van Deventer SJ, Jansen PL, Konstantinova P. Reseau Centre de Ressources Biologiques Foie F (2012) Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 55(3): 821-832.
6. Burkhart CA, Watt F, Murray J, Pajic M, Prokvolit A, Xue C, Flemming C, Smith J, Purmal A, Isachenko N, Komarov PG, Gurova KV, Sartorelli AC, Marshall GM, Norris MD, Gudkov AV, Haber M (2009) Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res 69(16): 6573-6580.
7. Cai KQ, Wu H, Klein-Szanto AJ, Xu XX (2009) Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity. Gynecol Oncol 114(1): 18-25.
8. Cavallaro U, Christofori G (2001) Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta 1552(1): 39-45.
9. Chen Z, Liu F, Ren Q, Zhao Q, Ren H, Lu S, Zhang L, Han Z (2010) Suppression of ABCG2 inhibits cancer cell proliferation. Int J Cancer 126(4): 841-851.
10. Dabrowska M, Sirotnak FM (2004) Regulation of transcription of the human MRP7 gene. Characteristics of the basal promoter and identification of tumor-derived transcripts encoding additional 5 end heterogeneity. Gene 341: 129-139.
11. Dave B, Mittal V, Tan NM, Chang JC (2012) Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 14(1): 202.
12. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR, Muller WJ, Moses HL (2005) Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 65(6): 2296-2302.
13. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1(1): 27-42.
14. Grassilli E, Narloch R, Federzoni E, Ianzano L, Pisano F, Giovannoni R, Romano G, Masiero L, Leone BE, Bonin S, Donada M, Stanta G, Helin K, Lavitrano M (2013) Inhibition of GSK3B Bypass drug resistance of p53-Null colon carcinomas by enabling necroptosis in response to chemotherapy. Clin Cancer Res 19(14): 3820-3831.
15. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89(22): 10578-10582.
16. Harrell FE (2001) Regression Modeling Strategies. In Chapter 2, pp 11-40. Springer: New York, NY.
17. Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming CL, Smith J, Fletcher JI, Gherardi S, Kwek CK, Russell AJ, Valli E, London WB, Buxton AB, Ashton LJ, Sartorelli AC, Cohn SL, Schwab M, Marshall GM, Perini G, Norris MD (2011) ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 103(16): 1236-1251.
18. Higgins MJ, Baselga J (2011) Targeted therapies for breast cancer. J Clin Invest 121(10): 3797-3803.
19. Hirohashi S (1998) Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 153(2): 333-339.
20. Hlavac V, Brynychova V, Vaclavikova R, Ehrlichova M, Vrana D, Pecha V, Kozevnikovova R, Trnkova M, Gatek J, Kopperova D, Gut I, Soucek P (2013) The expression profile of ATP-binding cassette transporter genes in breast carcinoma. Pharmacogenomics 14(5): 515-529.
21. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, Liska V, Pitule P, Novak P, Bruha J, Vycital O, Holubec L, Treska V, Vodicka P, Soucek P (2012) The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 27(2): 187-196.
22. Hoffmann K, Shibo L, Xiao Z, Longerich T, Buchler MW, Schemmer P (2011) Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma. Anticancer Res 31(11): 3883-3890.
23. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD (2004) Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64(14): 4927-4930.
24. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD (2009) Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res 69(1): 178-184.
25. Hopper-Borge EA, Churchill T, Paulose C, Nicolas E, Jacobs JD, Ngo O, Kuang Y, Grinberg A, Westphal H, Chen ZS, Klein-Szanto AJ, Belinsky MG, Kruh GD (2011) Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10 (-/-) mice. Cancer Res 71(10): 3649-3657.
26. Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, Kruh GD (2001) Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett 162(2): 181-191.
27. Huang FF, Wu DS, Zhang L, Yu YH, Yuan XY, Li WJ, Chen XP, Zhao XL, Chen FP, Zeng H (2013) Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett 336(1): 96-105.
28. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH (2005) MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. IntJ Cancer 116(5): 824-829.
29. Imai Y, Yamagishi H, Ono Y, Ueda Y (2012) Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells. Clin Transl Med 1(1): 24.
30. Ishihara D, Dovas A, Hernandez L, Pozzuto M, Wyckoff J, Segall JE, Condeelis JS, Bresnick AR, Cox D (2013) Wiskott-Aldrich syndrome protein regulates leukocyte-dependent breast cancer metastasis. Cell Rep 4(3): 429-436.
31. Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M, Egleston BL, Klein-Szanto A, Pugacheva EN, Hardy RR, Wolfson M, Connolly DC, Golemis EA (2009) NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res 69(18): 7198-7206.
32. Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, Fojo T, Bates SE (2012) A pharmacodynamic study of the P-glycoprotein antagonist CBT-1(R) in combination with paclitaxel in solid tumors. Oncologist 17(4): 512.
33. Keppler D (2011) Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol 201: 299-323.
34. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7): 844-847.
35. Kuo PL, Hsu YL, Cho CY (2006) Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther 5(12): 3209-3221.
36. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163(5): 2113-2126.
37. Malofeeva E, Domanitskaya N, Gudima M, Hopper-Borge EA (2012) Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res 72(24): 6457-6467.
38. Marcotte R, Smith HW, Sanguin-Gendreau V, McDonough RV, Muller WJ (2012) Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. Proc Natl Acad Sci USA 109(8): 2808-2813.
39. McMillin DW, Negri JM, Mitsiades CS (2013) The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 12(3): 217-228.
40. Mohelnikova-Duchonova B, Brynychova V, Oliverius M, Honsova E, Kala Z, Muckova K, Soucek P (2013) Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. Pancreas 42(4): 707-716.
41. Naramoto H, Uematsu T, Uchihashi T, Doto R, Matsuura T, Usui Y, Uematsu S, Li X, Takahashi M, Yamaoka M, Furusawa K (2007) Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. Int J Oncol 30(2): 393-401.
42. O'Donovan N, Crown J, Stunell H, Hill AD, McDermott E, O'Higgins N, Duffy MJ (2003) Caspase 3 in breast cancer. Clin Cancer Res 9(2): 738-742.
43. Oguri T, Ozasa H, Uemura T, Bessho Y, Miyazaki M, Maeno K, Maeda H, Sato S, Ueda R (2008) MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther 7(5): 1150-1155.
44. Parsons M, Heike G (2009) How to make tissue microarrays. Diagn Histopathol 15(3): 142-149.
45. Pick A, Wiese M (2012) Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway. ChemMedChem 7(4): 650-662.
46. Shults J, Ratcliffe SJ, Leonard M (2007) Improved generalized estimating equation analysis via xtqls for implementation of quasi-least squares in Stata. Strata J 7(2): 147-166.
47. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3.
48. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW (2008) An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107(3): 309-330.
49. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, Blanchard RA, Lee JC, King TC, Rosenberg CL (2009) Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 11(2): R18.
50. Sui M, Huang Y, Park BH, Davidson NE, Fan W (2007) Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res 67(11): 5337-5344.
51. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6(2): 129-137.
52. Takayanagi S, Kataoka T, Ohara O, Oishi M, Kuo MT, Ishikawa T (2004) Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation. J Exp Ther Oncol 4(3): 239-246.
53. Ueno NT, Yu D, Hung MC (1997) Chemosensitization of HER-2/neu- overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 15(8): 953-960.
54. Wang P, Zhang Z, Gao K, Deng Y, Zhao J, Liu B, Li X (2009) Expression and clinical significance of ABCC10 in the patients with non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 12(8): 875-878.
55. Woodward EJ, Twelves C (2010) Scheduling of taxanes: a review. Curr Clin Pharmacol 5(3): 226-231.
56. Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, Tanabe M, Chishima T, Sasaki T, Ichikawa Y, Morita S, Yoshiura K, Takabe K, Endo I (2013) High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat 137(3): 773-782.